Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

F-Prime Capital

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 443
Average round size
info
The average size of a deal this fund participated in
$39M
Portfolio companies 247
Rounds per year 5.68
Lead investments 25
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.44
Exits 63
Key employees 11
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Software
  • Therapeutics

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of F-Prime Capital:
Typical Co-investors
F-Prime Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after F-Prime Capital:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Comanche Biopharma

Biopharma
Biotechnology
Pharmaceutical
$75M17 Jan 2024 Concord, Massachusetts, United States

OneAdvisory

Finance
Financial Services
$8M11 Jan 2024 Miami, Florida, United States

Augean Robotics

AgTech
Robotics
$24M09 Jan 2024 Philadelphia, Pennsylvania, United States

Genomics

Biopharma
Biotechnology
Genetics
Health Care
Life Science
Medical
Therapeutics
$47M08 Jan 2024 Oxford, England, United Kingdom

OnCusp Therapeutics

Biotechnology
Health Care
Pharmaceutical
Product Research
$100M04 Jan 2024 New York, New York, United States

Shinobi Therapeutics

Biotechnology
Therapeutics
$51M12 Dec 2023 -

ARTBIO

Biotechnology
Health Care
Hospital
Medical
Medical Device
Pharmaceutical
$90M07 Dec 2023 Oslo, Norway

T-Therapeutics

Biotechnology
Health Care
Medical
$65M15 Nov 2023 Cambridge, Cambridgeshire, United Kingdom

Eleos Health

Health Care
$40M08 Nov 2023 Cambridge, Massachusetts, United States
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Centivo raises $51 million as more employers seek affordable, quality healthcare for their employees

– Centivo, a new health plan for self-funded employers that is anchored around leading providers of value-based care, announced today that it has raised an additional $51 million in funding.
B Capital Group, a leading global technology investor, and Maverick co-led the round.
– Additional existing investors, including Bain Capital Ventures, Company Ventures, Define Ventures, F-Prime Capital, HarbourVest Partners, Ingleside Investors, Nassau Street Ventures, an AVG fund and various individuals also participated.
– These funds will support Centivo’s rapid growth and expansion amid increased demand from employers for health plans that are structurally built to address employee healthcare affordability.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent F-Prime Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 443
Average round size 39M
Rounds per year 5.68
Peak activity year 2021
Lead investments 25
Follow on index 0.44
Exits 63
Group Appearance index 0.93

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Comanche Biopharma

Biopharma
Biotechnology
Pharmaceutical
$75M17 Jan 2024 Concord, Massachusetts, United States

OneAdvisory

Finance
Financial Services
$8M11 Jan 2024 Miami, Florida, United States

Augean Robotics

AgTech
Robotics
$24M09 Jan 2024 Philadelphia, Pennsylvania, United States

Genomics

Biopharma
Biotechnology
Genetics
Health Care
Life Science
Medical
Therapeutics
$47M08 Jan 2024 Oxford, England, United Kingdom

OnCusp Therapeutics

Biotechnology
Health Care
Pharmaceutical
Product Research
$100M04 Jan 2024 New York, New York, United States

Shinobi Therapeutics

Biotechnology
Therapeutics
$51M12 Dec 2023 -

ARTBIO

Biotechnology
Health Care
Hospital
Medical
Medical Device
Pharmaceutical
$90M07 Dec 2023 Oslo, Norway

T-Therapeutics

Biotechnology
Health Care
Medical
$65M15 Nov 2023 Cambridge, Cambridgeshire, United Kingdom

Eleos Health

Health Care
$40M08 Nov 2023 Cambridge, Massachusetts, United States
Crunchbase icon

Content report

The following text will be sent to our editors: